Clinical trials: Clopidogrel, completed
Coronary Artery Disease
Clopidogrel and Response Variability Investigation Study 2
To evaluate the role of the genetic variant 2C19*2 on the pharmacodynamic response as assessed by optical aggregometry and on the pharmacokinetic response as assessed by measuring active metabolites following an oral…
- Trial name
- CLOVIS2 (NCT00822666)
- Testing
- clopidogrel
- Where
- France
- Volunteers
- 109 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bioequivalence
Bioequivalence Study of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® 75 mg Tablet After Oral Administration to Healthy Adult Subjects Under Fasting Condition
To compare the rate and extent of absorption of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® (clopidogrel) 75 mg tablet under fasting condition.
- Trial name
- NCT05186129
- Testing
- Clopid® 75 mg Tablet, Plavix® 75mg Tablet
- Where
- Pakistan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Center for Bioequivalence Studies and Clinical Research
Ischemic Stroke
Clopidogrel Response in Acute Ischemic Stroke
The aim of this study was to determine the prevalence rate and risk factors for chemical laboratory clopidogrel low-response (CLR) in the acute phase after an ischemic stroke.
- Trial name
- Bo-CRISP (NCT01846572)
- Volunteers
- 159 people
- Sponsor
- Ruhr University of Bochum
Coronary Artery Disease
Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole
Clopidogrel, an inhibitor of ADP induced platelet aggregation and activation, is one of the most commonly used drugs in patients with cardiovascular disease.
- Trial name
- NCT01094275
- Testing
- Clopidogrel 75mg, Omeprazole 20mg
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Neil Kleiman, MD
ST Elevated Myocardial Infarction
Neutrophil/Lymphocyte (N/L) Ratio and Long Term Follow-up in ST-elevation Myocardial Infarction
Although the pre-procedural neutrophil to lymphocyte ratio (N/L) has been associated with adverse outcomes among patients with coronary artery disease, its role during the acute phase of ST-segment elevation myocardial infarction…
- Trial name
- NCT01663194
- Testing
- primary percutaneous coronary intervention, each groups
- Where
- Turkey (Türkiye)
- Volunteers
- 1,034 people
- Sponsor
- TC Erciyes University
Cervical Artery Dissection, Carotid Artery Dissection
To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection
This is a feasibility study to determine if a sufficient number of patients can be recruited throughout the United Kingdom and whether sufficient endpoints can be generated for a full scale therapeutic trial of anticoagulants…
- Conditions
- Cervical Artery Dissection, Carotid Artery Dissection, Vertebral Artery Dissection, Stroke
- Trial name
- CADISS (NCT00238667)
- Testing
- Antiplatelet (Aspirin, Dipyridamole, clopidogrel), Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- St George's, University of London
Coronary Artery Disease, Stent Thrombosis
Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation
To compare treatment with aspirin alone versus the combined antiplatelet treatment aspirin and clopidogrel after 12 months of combined antiplatelet treatment following drug-eluting stent (DES) implantation.
- Conditions
- Coronary Artery Disease, Stent Thrombosis, Myocardial Ischemia
- Trial name
- OPTIDUAL (NCT00822536)
- Testing
- Aspirin and Clopidogrel, Aspirin
- Where
- France
- Volunteers
- 1,798 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ACUTE KIDNEY INJURY
Nephrologic Intervention in Patients Waiting for Cardiac Surgery
Acute kidney injury (AKI) is a frequent complication after cardiac surgery. Its incidence ranges from 19 to 44% depending on the study and which definition is used: Acute Kidney Injury Network (AKIN) classification or RIFLE…
- Trial name
- AKIIcor (NCT02643745)
- Testing
- Nephrology Intervention
- Where
- Spain
- Volunteers
- 410 people
- Sponsor
- Hospital Universitari de Bellvitge
Coronary Artery Disease, Drug Resistance
Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition
This study is a prospective, single-center evaluation of the efficacy of clopidogrel dose adjustment in patients with insufficient platelet inhibition after elective coronary stent implantation.
- Trial name
- NCT00302913
- Testing
- Adjustment of clopidogrel dose
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- University Heart Center Freiburg - Bad Krozingen
Healthy
The Antiplatelet and Immune Response Trial
Platelets are the main type of blood cell involved in the formation of blood clots that cause heart attacks. The investigators give antiplatelet drugs (aspirin, for example) to reduce the risk of another clot forming in the…
- Trial name
- NCT01846559
- Testing
- Endotoxin, Clopidogrel, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Acute ST Segment Elevation Myocardial Infarction, Thrombolysis in Myocardial Infarction Flow
Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis
Administration of Ticagrelor in patients with ST elevation myocardial infarction treated with pharmacological thrombolysis
- Trial name
- TREAT (NCT02298088)
- Testing
- Ticagrelor 180 mg, Clopidogrel
- Where
- 153 sites in Argentina, Australia and 8 more
- Volunteers
- 3,799 people
- Sponsor
- Hospital do Coracao
Stable Coronary Artery Disease
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- RESPOND (NCT00642811)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Healthy
Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male Subjects
Study to assess the influence of 75 mg clopidogrel on the pharmacodynamics and safety of 100 mg terbogrel bid.
- Trial name
- NCT02222987
- Testing
- Terbogrel, Clopidogrel
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
PRIMARY HYPOTHESIS: Compared with intensive medical therapy alone, intracranial angioplasty and stenting combined with intensive medical therapy will decrease the risk of the primary endpoint by 35% over a mean follow-up of two…
- Trial name
- SAMMPRIS (NCT00576693)
- Testing
- intracranial angioplasty and stenting, intensive medical management
- Where
- 50 sites in United States
- Volunteers
- 451 people
- Sponsor
- Medical University of South Carolina
Platelet Dysfunction Due to Drugs
The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease
This study aims to assess the effects of low dose ticagrelor on platelet function testing in patients with stable coronary artery disease.
- Trial name
- TWIST (NCT04206176)
- Testing
- Ticagrelor
- Where
- Trinidad and Tobago
- Volunteers
- 25 people
- Sponsor
- The University of The West Indies
Angina Pectoris, Coronary Artery Disease
Effects of Integrated Treatment by Traditional Chinese and Western Medicine in Reducing Cardiovascular Events
Compared with standardized western medical drug therapy, this study is mainly about whether the combination of standardized western medical drug therapy and Chinese medical continued treatment, can further decrease the rate of…
- Conditions
- Angina Pectoris, Coronary Artery Disease, Coronary Disease, Heart Disease
- Trial name
- NCT01715376
- Where
- China
- Volunteers
- 1,042 people, healthy volunteers welcome
- Sponsor
- Changchun University of Chinese Medicine
Inflammation, Thrombosis
Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients
This is a prospective, randomized, parallel design study to investigate that ticagrelor could attenuate inflammatory cell infiltration in thrombus aspirated from ST elevation myocardial infarction (STEMI) patients.
- Trial name
- NCT02639143
- Testing
- ticagrelor, Clopidogrel
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Peripheral Arterial Disease, Clopidogrel, Poor Metabolism of
Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease
This study evaluates the effects of Aspirin and thienopyridine resistance in relation to clinical cardiovascular outcomes as the genetic predictors of, and outcomes associated with aspirin and thienopyridine resistance in…
- Trial name
- NCT03174990
- Where
- United States
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Cardiovascular Disease, Acute Coronary Syndrome
Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence
Percutaneous coronary intervention (PCI) is a common invasive cardiovascular procedure performed in the VA with over 13,000 procedures in FY10.
- Trial name
- NCT01609842
- Testing
- Multifaceted Intervention with pharmacist and IVR
- Where
- 15 sites in United States
- Volunteers
- 14,573 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Antiplatelet Aggregation
A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic Patients
The purpose of the study is to look at the biomarkers of inflammation and platelet activation in patients with drug eluting stents implanted approximately 12 months ago on aspirin and statin, for a 4-week period after the routine…
- Trial name
- DECADES (NCT00493779)
- Testing
- Blood Collection
- Where
- 6 sites in France, Germany and 2 more
- Volunteers
- 103 people
- Sponsor
- Bristol-Myers Squibb